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Available online 17 January 2017Fibroblast growth factor-23 (FGF23) controls key responses to systemic phosphate increases through its
phosphaturic actions on the kidney. In addition to stimulation by phosphate, FGF23 positively responds to iron
deﬁciency anemia and hypoxia in rodent models and in humans. The disorder X-linked hypophosphatemia
(XLH) is characterized by elevated FGF23 in concert with an intrinsic bone mineralization defect. Indeed, the
Hypmouse XLHmodel has disturbed osteoblast to osteocyte differentiationwith altered expression of a wide va-
riety of genes, including FGF23. The transcription factor Hypoxia inducible factor-1α (HIF1α) has been implicat-
ed in regulating FGF23 production and plays a key role in proper bone cell differentiation. Thus the goals of this
studywere to determinewhetherHIF1α activation could inﬂuence FGF23, and to test osteoblastic HIF1α produc-
tion on the Hyp endocrine and skeletal phenotypes in vivo. Treatment of primary cultures of osteoblasts/osteo-
cytes and UMR-106 cells with the HIF activator AG490 resulted in rapid HIF1α stabilization and increased
Fgf23 mRNA (50–100 fold; p b 0.01–0.001) in a time- and dose-dependent manner. Next, the Phex gene deletion
in the Hypmouse was bred onto mice with a HIF1α/Osteocalcin (OCN)-Cre background. Although HIF1α effects
on bone could be detected, FGF23-related phenotypes due to the Hypmutation were independent of HIF1α in
vivo. In summary, FGF23 can be driven by ectopic HIF1α activation under normal iron conditions in vitro, but fac-
tors independent of HIF1α activity after mature osteoblast formation are responsible for the disease phenotypes
in Hypmice in vivo.
© 2017 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The hormone FGF23 is produced in osteoblasts/osteocytes and plays
a central role in renal phosphate handling. FGF23 acts in the kidney
via its co-receptor αKlotho (αKL) and ﬁbroblast growth factor
receptors (FGFRs) to suppress renal phosphate reabsorption and reduce
1,25(OH)2 vitamin D (1,25D) production (Shimada et al., 2001; Larsson
et al., 2004). Serum FGF23 is known to increase following dietary phos-
phate challenge (Antoniucci et al., 2006) as well as after 1,25D delivery
(Shimada et al., 2005). Unique insight into the systemic control of FGF23
has been gained through the study of the disorder autosomal dominant
hypophosphatemic rickets (ADHR) (ADHR-Consortium, 2000). Inter-
estingly, patients with late-onset ADHR have elevated FGF23 and dis-
ease manifestations that originate during physiological situations of
iron deﬁciency, including puberty and pregnancy (Econs and McEnery,& Molecular Genetics, Indiana
B130, Indianapolis, IN 46202,
en access article under the CC BY-NC1997).We previously determined ADHR knock-in mice (carrying a cor-
responding human R176Q-Fgf23 mutant allele) markedly increased
bone Fgf23 mRNA during iron deﬁciency anemia, leading to a
hypophosphatemic rickets phenotype (Farrow et al., 2011). The rela-
tionships between iron metabolism and FGF23 are further reﬂected by
highly signiﬁcant negative correlations between total serum iron con-
centrations and FGF23 in ADHR kindreds (Imel et al., 2011), and in ane-
mic patients treated with speciﬁc iron preparations (Shimizu et al.,
2009; Wolf et al., 2013; Schouten et al., 2009a; Schouten et al., 2009b).
In cultured osteoblastic cells, FGF23 can be induced by hypoxia and fol-
lowing iron chelation with deferoxamine (DFO), occurring in concert
with marked protein accumulation of the transcription factor Hypox-
ia-induced factor-1α (HIF) (Farrow et al., 2011; Clinkenbeard et al.,
2014). The HIF1α and 2α transcription factors play key roles in cellular
responses to oxygen/iron sensing (Ivan et al., 2001). In addition to con-
trolling genes such as erythropoietin (EPO) in kidney and vascular en-
dothelial growth factor (VEGF) in many tissues (Yousaf and Spinowitz,
2016; Cubranic et al., 2015), HIFs plays essential roles in bone develop-
ment. HIFs are required for proper osteogenesis and joint formation
(Wang et al., 2007). Indeed, when deleted from mice, studies-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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a complex homeostatic response that allows chondrocyte to survival
and differentiation under hypoxic conditions (Schipani et al., 2001).
The metabolic bone disorder X-linked hypophosphatemia (XLH) is
caused by loss of function mutations in the Phosphate-regulating gene
with homologies to endopeptidases on the X chromosome (PHEX gene)
(Anon, 1995). Other members of this enzyme class include neutral en-
dopeptidase (NEP) and endothelin-converting enzymes 1 and 2 (ECE-
1 and ECE-2) (Turner and Tanzawa, 1997), which are known to cleave
small peptides. XLH is characterized by elevated bioactive FGF23, inap-
propriately low or normal 1,25D, and a hypophosphatemic rickets/oste-
omalacia phenotype. The orthologous XLH mouse model, Hyp, has a
large 3′ Phex deletion and phenocopies the XLH patient endocrine and
skeletal disease phenotypes (Miao et al., 2001), including low serum
phosphate, severe growth plate defects, and osteomalacia. In addition
to ricketic bone disease, the Hypmouse has a defect in osteoblast to os-
teocyte differentiation, with inappropriate expression of cell matrix
genes (Bai et al., 2004). FGF23 is highly elevated in Hyp whole bone
(Liu et al., 2006) as well as in Hyp-derived cultured osteoblasts/osteo-
cytes (Liu et al., 2003). Primary cultures of osteoblastic cells from Hyp
mice also fail to properly mineralize, thus underscoring an intrinsic cel-
lular defect due to only partially resolvedmechanisms (Bai et al., 2004).
FGF23 is central to the Hypmetabolic bone disease phenotype, as dem-
onstrated by the fact that global (Sitara et al., 2004) or osteoblast-specif-
ic (Clinkenbeard et al., 2016) knockout of Fgf23 in the Hyp genetic
background reverses, or rescues, respectively, the low serum phosphate
phenotype. However the molecular mechanisms controlling FGF23 in
Hyp remain unknown.
Since FGF23 is elevated in the Hyp mouse, in concert with work
linking HIF1α to increased FGF23 expression (Farrow et al., 2011;
David et al., 2016) and this transcription factor's signiﬁcant roles in
bone cell differentiation, we sought to determine whether FGF23
could be induced under normal iron conditions following HIF1α activa-
tion, as well as whether bone-speciﬁc HIF1α deletion would correct
FGF23 production and the Hyp disease phenotype. We found that in
vitro, ectopic HIF1α activation strongly induced FGF23 production in
primary cultures of differentiated osteoblasts/osteocytes, as well as in
osteoblastic cell lines. In contrast, conditional deletion of HIF1α in vivo
from mature osteoblasts demonstrated that FGF23 production in the
Hyp mouse was independent of this transcription factor. Collectively,
these ﬁndings further support the presence of unique mechanisms for
abnormal FGF23 production among the disorders of phosphate han-
dling involving this hormone.2. Materials and methods
2.1. Animal studies
Animal studies were performed according to the Institutional Ani-
mal Care and Use Committee (IACUC) for Indiana University, and com-
ply with the NIH guidelines for the use of animals. Hyp mice (Phex±)
were mated to conditionally null ﬂox(ﬂ)-Hif1α/Osteocalcin (OCN)-Cre
mice that lack Hif1α in the mature cells of the osteoblast-osteocyte lin-
eage as reported (Wan et al., 2008). This cross generated Hyp/Hif1αﬂ/ﬂ/
OCN-Cre+, hereafter referred to as ‘Hyp/Hif1α(Cre+)’ mice. The other
derived genotypes were: ‘WT,’ which were Phex+/+/Hif1αﬂ/ﬂ/OCN-
Cre−, as well as ‘WT/Hif1α(Cre+),’ which were: Phex+/+/Hif1αﬂ/ﬂ/
OCN-Cre+ genotype. Blood samples were collected at the time of sacri-
ﬁce by cardiac puncture according to approved protocols. Mouse
weightswere taken every otherweek. Serumbiochemistries weremea-
sured using an automated COBASMIRA Plus Chemistry Analyzer (Roche
Diagnostics; Indianapolis, IN). Serum intact bioactive FGF23 (iFGF23)
concentrations were assessed using a commercial rodent-speciﬁc
iFGF23 ELISA according to the manufacturer's protocol (Immutopics,
Int'l/Quidel, Corp.).2.2. Cell culture
UMR-106 cells (American Type Culture Collection; Manassas, VA)
and primary cultures of differentiated osteoblasts/osteocytes were cul-
tured in D-MEM/F-12 (Invitrogen) supplemented with 10% fetal bovine
serum (FBS) (Hyclone; Thermo-Fisher, Inc.; Waltham,MA), and 25mM
penicillin-streptomycin in normoxia (21%)with 5% CO2/95% air at 37 °C.
Primary cultures of osteoblasts/osteocytes were obtained from calvarial
bones of neonatal C57BL/6 mice and were supplementedwith 50 μg/ml
ascorbic acid as previously reported (Bellido et al., 2005). Cells were
treated with varying concentrations of AG490 in 12 well and 24 well
plates, incubated 30 min to 24 h for time course trials and 8 and 24 h
for dose-dependent studies. AG409 was diluted with the vehicle di-
methyl sulfoxide (DMSO). UMR-106 cells were pre-treated with the
MEK inhibitor (10 μM; U0126, R&D Systems).2.3. RNA preparation and quantitative RT-PCR (qPCR)
The primary osteoblast/osteocyte cultures and UMR-106 cells were
lysed in RLT buffer (Qiagen, Inc.) and homogenized in a Bullet Blender
(MidSci Inc.). Total RNA from lysates was prepared using the RNeasy
Kit (Qiagen, Inc.). RNA samples were tested with intron-spanning
primers speciﬁc for mouse Fgf23 and normalized to β-actin as an inter-
nal control. All qPCR primers and probes were purchased as pre-opti-
mized reagents (Applied Biosystems, Inc.). The TaqMan One-Step RT-
PCR kit was used to perform qPCR. PCR conditions for all experiments
were: 30 min 48 °C, 10 min 95 °C, followed by 40 cycles of 15 s 95 °C
and 1 min 60 °C. The data was collected and analyzed by the 7500
Real Time PCR system and software (Applied Biosystems). RNA samples
were analyzed in duplicate, and the 2−ΔΔCT method described by Livak
was used to analyze the data (Livak and Schmittgen, 2001).2.4. Western blot analysis
UMR-106 cellswere lysedwith 100 μL 1× Lysis buffer (Cell Signaling
Technologies, Inc.) with 1 μg/mL AEBSF protease inhibitor (Sigma-Al-
drich, Inc.). Cell lysate protein concentrations were determined with
the Better Bradford Kit (Thermo-Fisher Scientiﬁc) according to the
manufacturer's instructions. Western blot analysis was performed as
previously described (Larsson et al., 2005) with 50 μg UMR-106 cellular
lysates. The blots were incubated with 1:1000 primary anti-Hif1α;
(Novus Biologicals) then incubated with the appropriate secondary an-
tibody at 1:3000 (anti-rabbit IgG-HRP; Bio-Rad, Inc.); for normalization
blots were stripped and incubated with 1:25,000 anti-β-actin-HRP
(Sigma). Detection was performed using the ECL-Plus Western Blotting
Detection Reagents (Amersham-GE Healthcare) and X-OMAT ﬁlm
(Eastman-Kodak Co.; Rochester, NY).2.5. Micro-computed tomography
Morphological parameters of the distal femur were assessed using
high resolution micro-computed tomography (μCT; Skyscan 1172).
Bones were wrapped in paraﬁlm to prevent drying during scanning.
Scans were obtained using an X-ray source set at 60 kV and 167 mA
over an angular range of 180° (rotational steps of 0.70°) with a
6 μm pixel size. Projection images were reconstructed using standard
Skyscan software (NRecon). A 0.5 mm region of interest of the in the
distal femur metaphysis was analyzed by segmenting the trabecular
bone from the cortical shell and calculating trabecular bone volume
per total volume (BV/TV) in accordance with recommended guidelines
(13). On the most proximal slice of the ROI, the cortical shell was man-
ually isolated from the trabecular bone by tracing the periosteal and
endocortical edges for assessment of cortical bone geometry.
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Where applicable ANOVA analysis with a Tukey HSD post-hoc test
was conducted. Male and female Hyp, and Hyp/Hif1α(Cre+) were com-
pared to their respective WT and WT/Hif1α(Cre+) genotype controls
using Student's t-test. Signiﬁcance for all tests was set at p b 0.05 and
data are presented as means ± standard error of the mean (SEM).
3. Results
3.1. HIF activity is upstream of FGF23
To test the role of HIF activation on the control of FGF23, the com-
poundAG409wasused, as this analog strongly activatesHIF1α in isolat-
ed cell systems (Fernandez-Sanchez et al., 2012). In this regard, primary
cultures of differentiated osteoblasts/osteocytes and the osteoblastic
UMR-106 cell line were treated with AG490, and Fgf23 mRNA expres-
sion was examined by qPCR. After 24 h, Fgf23 mRNA increased N160-
fold in the primary cultures (p b 0.001; Fig. 1A), and 30-fold in UMR-
106 cells (p b 0.01, Fig. 1B). In addition, AG490 treatment also potently
stabilized Hif1α protein as determined by immunoblot (Fig. 1B, inset).
To determine the extent of the effects of AG490 on Fgf23 mRNAFig. 1. AG490 activity on Fgf23 mRNA expression in vitro. A. AG490 (50 μM) stimulated FGF23m
and B. UMR-106 cells (**p b 0.001). Inset: Hif1α protein was stabilized by both AG490 (50 μM
expression in UMR-106 cells versus vehicle (DMSO) after 2 h (*p b 0.05; **p b 0.01). E. AG49
(*p b 0.05 vs untreated and U0126; @p b 0.05 vs AG490 treated).expression, time- and dose-dependence was examined in UMR-106
cells. Fgf23 mRNA increased from 4 to 24 h with a maximum response
of 30-fold (p b 0.05–0.01; Fig. 1C), with doses of 10–50 μM (Fig. 1D).
Pre-treatment with a MEK inhibitor (U0126) signiﬁcantly blunted
AG490-induced Fgf23 mRNA expression (p b 0.05; Fig. 1E).
3.2. Osteoblast lineage-speciﬁc Hif1α deletion on the Hyp background
To test the role of Hif1α on the XLH-like phenotypes in vivo, the Phex
gene deletion in the XLH model mouse Hypwas bred onto the HIF1α/
Osteocalcin (OCN)-Cre background. Mice were serially assessed then
sacriﬁced at 12 weeks of age. By 6 weeks of age, WT and WT/
Hif1α(Cre+) males were signiﬁcantly heavier than Hyp and Hyp/
Hif1α(Cre+) (Fig. 2A; p b 0.01) and WT and WT/Hif1α(Cre+) females
were signiﬁcantly heavier than Hyp and Hyp/Hif1α(Cre+) female mice
by 12weeks (Fig. 2A; p b 0.05). Therewere nodifferences in theweights
between either male or female WT and WT/Hif1α(Cre+) or between
Hyp and Hyp/Hif1α(Cre+). Consistent with the known phenotype of
Hyp, serum phosphate at sacriﬁcewas reduced in bothmale and female
Hyp and Hyp/Hif1α(Cre+) mice (Table 1; p b 0.01). Alkaline phospha-
tase was increased in Hyp and Hyp/Hif1α(Cre+) mice compared to
their respective gender and genotype controls of WT and WT/RNA expression in primary cultures of differentiated osteoblasts/osteocytes (**p b 0.001)
) as assessed by immunoblot. (C.) Time- and (D.) dose-dependent effects on Fgf23 mRNA
0 (50 μM) activity on FGF23 mRNA expression is affected by pre-treatment with U0126
Fig. 2.Effects of Hif1α(Cre+) onHypphenotypes, A&B. Bodyweights (g) ofmale (left) and female (right)WT,WT/Hif1α(Cre+),Hyp, andHyp/Hif1α(Cre+)micewere recorded every other
week fromweeks 4 through12. (n ≥ 6mice per group; *p b 0.01, #p b 0.05). C. Serum intact FGF23was elevated inHyp versusWT in thepresence or absence of theHif1α(Cre) allele. Female
Hyp/Hif1α(Cre+) mice had slightly higher serum FGF23 compared with female Hyp. Bone structure in control and Hyp genetic crosses. Representative μCT images of distal femurs from
12week oldWT,WT/Hif1α(Cre+),Hyp, andHyp/Hif1α(Cre+); D.male (left panel), E. female (right panel). Compared to genotype controls,Hypmice hadmarkedlywidened distal femur
(white arrows) consistent with their known ricketic phenotype, as well as far less trabecular bone.
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types occurred for calcium, creatinine or total iron (Table 1). Serum in-
tact FGF23was increased inmale and female Hyp andHyp/Hif1α(Cre+)
mice compared to WT controls (Fig. 2B; p b 0.01).
μCT analysis of the distal femur showed qualitative changes in
Hyp and Hyp/Hif1α(Cre+) bone morphology including reduced
metaphysis and growth plate versus gender- and genotype-matched
WT controls (Fig. 2D & E). The Hyp and Hyp/Hif1α(Cre+) mice had
lower trabecular bone volume (BV/TV), trabecular separation
(Tb.Sp.), and trabecular number (Tb.N) (Table 2; Hyp male andTable 1
Serum biochemistries for WT, WT/Hif1α(Cre+), Hyp, and Hyp/Hif1α(Cre+) mice (#p b 0.01; *p
Alk. Phos. Phos
Male WT 91.57
±5.35
11.7
±0.
WT-Hif1α(Cre+) 78.00
±12.00
14.6
±2.
Hyp 416.62#
±17.57
8.92
±0.4
Hyp-Hif1α(Cre+) 410.50#
±28.52
9.55
±1.1
Female WT 114.90
±3.48
12.1
±1.
WT-Hif1α(Cre+) 114.00
±3.96
11.6
±0.
Hyp 275.50#
±13.99
7.65
±0.4
Hyp-Hif1α(Cre+) 276.43#
±12.17
8.94
±0.8females p b 0.01; Hyp/Hif1α(Cre+) male p b 0.01; Hyp/Hif1α(Cre+)
female p b 0.05). Male Hyp and Hyp/Hif1α(Cre+) mice displayed
larger bone area (B.Ar), compared to male WT and WT/Hif1α(Cre+)
(p b 0.01) as well as lower cortical thickness (Ct.Th) (p b 0.01). Fe-
male WT/Hif1α(Cre+) mice exhibited decreased Ct.Th compared to
WT females (p b 0.05), in line with previously reported bone effects
of osteoblastic-speciﬁc Hif1α deletion (Wan et al., 2008). Collective-
ly, these studies are consistent with the concept that in vitro Fgf23
mRNA is elevated during Hif1α activation, however FGF23 expres-
sion and the downstream metabolic bone disease phenotypes inb 0.05; compared to genotype control).
phate Calcium Creatinine Total iron
4
71
11.79
±0.54
0.42
±0.04
209.18
±12.08
3
46
11.06
±0.20
0.43
±0.04
220.73
±16.95
*
5
10.50
±0.37
0.40
±0.03
240.27
±10.60
*
9
10.86
±0.26
0.35
±0.04
233.24
±12.13
3
03
10.95
±0.30
0.33
±0.04
206.89
±8.70
0
47
10.65
±0.30
0.41
±0.04
214.77
±8.70
*
6
10.43
±0.19
0.40
±0.01
200.77
±12.32
*
5
9.95
±0.31
0.32
±0.05
231.68
±15.33
Table 2
μCT analysis in femur fromWT,WT/Hif1α(Cre+),Hyp, andHyp/Hif1α(Cre+)mice (#p b 0.01; *p b 0.05; compared to appropriate genotype control); (^p b 0.05; compared to femaleWT);
bone volume/trabecular volume (BV/TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), trabecular number (Tb.N), cross-sectional area (CSA), bone area (B.Ar), marrow area
(M.Ar), mean polar moment of inertia (MMI(polar)), cortical thickness (Ct.Th). Averages reported with ± the standard error of the mean.
Trabecular bone Cortical bone
BV/TV Tb.Th Tb.Sp Tb.N CSA B.Ar M.Ar MMI(polar) Ct.Th
Male
WT 12.33
±1.112
0.05
±0.002
0.20
±0.006
2.32
±0.137
2.07
±0.060
1.02
±0.043
1.05
±0.028
0.56
±0.046
0.15
±0.005
WT/HIF1α
(Cre+)
17.43
±1.327
0.06
±0.001
0.19
±0.006
3.02
±0.199
2.27
±0.086
1.10
±0.031
1.18
±0.065
0.67
±0.049
0.16
±0.004
Hyp 3.62#
±0.635
0.07#
±0.003
0.40#
±0.008
0.52#
±0.075
2.02
±0.070
0.70#
±0.028
1.32*
±0.048
0.41*
±0.035
0.10*
±0.002
Hyp/HIF1α
(Cre+)
2.70#
±1.089
0.06
±0.002
0.41#
±0.015
0.41#
±0.142
1.91*
±0.060
0.68*
±0.018
1.23
±0.051
0.36*
±0.021
0.10*
±0.004
Female
WT 4.88
±0.511
0.05
±0.002
0.26
±0.010
1.05
±0.096
1.90
±0.024
0.97
±0.016
0.93
±0.015
0.47
±0.016
0.20
±0.001
WT/HIF1α
(Cre+)
5.77
±1.338
0.05
±0.002
0.27
±0.041
1.18
±0.227
1.84
±0.040
0.90
±0.064
0.95
±0.053
0.43
±0.030
0.16^
±0.017
Hyp 1.12#
±0.184
0.07*
±0.006
0.45#
±0.008
0.16#
±0.026
1.79
±0.049
0.78#
±0.039
1.00
±0.083
0.38#
±0.013
0.12#
±0.008
Hyp/HIF1α
(Cre+)
1.40*
±0.253
0.08#
±0.006
0.44*
±0.007
0.18*
±0.028
1.67
±0.061
0.77
±0.044
0.90
±0.037
0.35
±0.037
0.13
±0.009
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blastic Hif1α.
4. Discussion
The heritable syndromes ofmineralmetabolism involving FGF23 are
genetically heterogeneous, therefore deﬁning themechanisms underly-
ing the distinct causes of elevated FGF23 and hypophosphatemia could
lead to disease-speciﬁc therapies. HIF activity in the skeleton is critical
for proper cell differentiation andmature bone development. In this re-
gard, HIF1α ablation demonstrated that this factor is critical for chon-
drocyte survival and differentiation with the known hypoxia in bone
tissue (Schipani et al., 2001), as well as for complete vascularization of
the growing tissue (Kotch et al., 1999). The Hyp mouse model was
shown to have defects in the maturation of osteoblasts to osteocytes,
with over-expression of type I collagen, as well as inappropriate expres-
sion of matrix proteins including bone sialoprotein, and vitronectin at
both the protein andmRNA levels (Bai et al., 2004). Our results showing
that direct activation of HIF1α is upstreamof Fgf23mRNA production is
consistent with studies demonstrating in vitro HIF1α activation and
ChIP isolation of Fgf23 cis-promoter activity downstream of or poten-
tially causing inﬂammatory responses (David et al., 2016; Singh et al.,
2016), which can be associated with functional iron deﬁciency.
It remains unclear how the loss of function mutations in PHEX result
in XLH, and cause both an intrinsic defect in bonemineralization and el-
evated FGF23. However reducing FGF23 bioactivity in patients
(Carpenter et al., 2014) and mouse models of XLH (Bai et al., 2016;
Erben et al., 2005) can reverse many of the severe manifestations of
this disorder. Recent studies have shown that FGF23 can be elevated
during situations of anemia in speciﬁc Fgf23-related disorders. This con-
cept arose from treatment of anemic patientswith speciﬁc iron prepara-
tions (Alleyne et al., 2008), prospective trials of iron formulations (Wolf
et al., 2013), as well as in the heritable disorder ADHR (Farrow et al.,
2011; Clinkenbeard et al., 2014). ADHR patients have FGF23 gain of
function mutations and can develop late onset disease with variable
penetrance, a unique ﬁnding among the FGF23 syndromes (Econs and
McEnery, 1997; Econs et al., 1997). In some cases, patients clearly doc-
umentedwith elevated FGF23 had a natural reversal of their renal phos-
phate wasting or stark disease onset during physiological situations
associated with anemia, such as puberty and pregnancy (Imel et al.,
2007). From this observation, Imel and colleagues tested FGF23 andserum total iron levels in ADHR patients and healthy controls and
found a signiﬁcant association with bioactive FGF23 only in ADHR kin-
dreds (Imel et al., 2011). These results were mimicked in mice contain-
ing ADHR R176Q-Fgf23 knock-in alleles. In this work, a low iron diet
increased Fgf23 mRNA in bone and raised plasma FGF23 in parallel,
leading to increased renal MEK signaling and to osteomalacia (Farrow
et al., 2011). In the context of an ADHR FGF23 mutation, the enhanced
transcription and more stable FGF23 protein led to elevated circulating
hormone, providing the molecular mechanism for this disease.
The XLH syndrome, like anemia-induced ADHR, is associated with
elevated Fgf23 mRNA, in concert with the inability to efﬁciently cleave
and inactivate bioactive FGF23 (Harrell et al., 1985). In a clinical study,
it was reported that although mean plasma FGF23 was elevated in pa-
tients with XLH compared to normals, FGF23 correlated negatively
with serum iron in both patients and normal controls (Imel et al.,
2014). This study suggested that the XLH disease phenotype was not
dependent upon serum iron concentrations. In contrast, a female pa-
tient from a family with a documented FGF23 ADHRmutation received
clinical beneﬁt from iron (II) sulfate therapy (Kapelari et al., 2015). This
treatment suppressed serum FGF23 and elevated 1,25D (Kapelari et al.,
2015), supporting the idea that restoring serum iron concentrations to
normal in anemic patients may help to reduce FGF23. Therefore, elevat-
ed bioactive FGF23 is the common denominator in multiple FGF23-re-
lated syndromes, however due to the lack of association between
serum iron levels and the XLH phosphate wasting phenotype, XLH pa-
tients may have higher beneﬁt from direct targeting of FGF23, such as
with anti-FGF23 antibody therapy (Carpenter et al., 2014). Although
we demonstrated HIF activity upstream of Fgf23 mRNA expression in
vitro, our studies may not have observed an FGF23-related phenotype
in Hypmice for several reasons. First, HIF2α has been shown to poten-
tially compensate for some phenotypes during osteoblastic HIF1α abla-
tion in vivo (Wang et al., 2007). Therefore signiﬁcant HIF2α expression
could potentially inﬂuence FGF23 expression in whole bone. In prior
studies, however, iron chelationwith DFO in UMR-106 cells failed to ac-
tivate HIF2α concomitant with elevated Fgf23 mRNA expression in-
creases (Clinkenbeard et al., 2014), therefore whether HIF2α is
activated in vivo in Hyp is unclear. Additionally, in the current study,
the late osteoblast osteocalcin promoter was used to conditionally tar-
get HIF1α as reported (Wang et al., 2007). Since Fgf23 mRNA is
expressed in a signiﬁcant proportion of osteoblasts (Feng et al., 2006),
due to the reported osteoblast to osteocyte transition defect in Hyp
43J.M. Hum et al. / Bone Reports 6 (2017) 38–43mice (Miao et al., 2001) Cre-mediated recombination of ﬂoxed-HIFs
may have to be targeted earlier in the osteoblastic differentiation stages
to more dramatically alter FGF23 production. Although we found in
UMR-106 cells that an AG490-mediated increase in Fgf23 mRNA was
potently induced, correlation between Fgf23 mRNA and FGF23 protein
remains to be determined. Finally, there is emerging evidence that
FGF23 is produced in cells that comprise bone outside of osteoblasts/os-
teocytes, such as chondrocytes (Kawai et al., 2013) and inmarrow (Xiao
et al., 2013). Therefore, whether these other sites compensate for oste-
oblast/osteocyte FGF23 production is currently unknown, and gives rise
to the idea that in the Hyp genetic background, multiple cell types may
have to be targeted to fully affect circulating FGF23 concentrations.
In summary, our studies support that HIF1α is functionally upstream
of FGF23 production in osteoblast/osteocyte cells. TheXLH phenotype of
elevated FGF23 and hypophosphatemic rickets due to loss of function
Phexmutations in the Hyp mouse however, is independent of mature
osteoblastic HIF1α expression. Therefore, the genetic heterogeneity of
diseases associated with elevated FGF23 must be considered during in-
dividual patient care, including targetingHIF-dependent pathwayswith
iron therapy or HIF inhibitors, ADHR, but likely not XLH.
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